文献速递淋巴瘤血栓与止血

侵袭性淋巴瘤亚型是静脉血栓形成的危险因素:淋巴瘤特异性静脉血栓预测模型的建立

Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.
PubMed 文献 · Am J Hematol · 2020-05-08

该回顾性分析比较了弥漫大B细胞淋巴瘤(DLBCL)与滤泡性淋巴瘤(FL)患者的静脉血栓栓塞(VTE)风险,纳入2002至2014年诊断的790例患者(DLBCL 542例,FL 248例),中位随访49个月。DLBCL的5年累积VTE发生率高于FL(16.3% vs 3.8%),合并VTE患者5年总生存率低于无VTE患者(51.4% vs 73.1%,P < .001)。在Khorana评分基础上加入淋巴瘤亚型、白蛋白、白细胞计数和巨块病变构建的新风险模型在验证队列中得到验证。

要点

  • DLBCL患者5年累积VTE发生率为16.3%,高于FL患者的3.8%。
  • 合并VTE的淋巴瘤患者5年总生存率为51.4%,低于无VTE患者的73.1%(P < .001)。
  • 包含淋巴瘤亚型、白蛋白、白细胞计数和巨块病变的新风险模型在验证队列中得到验证。

核心结论

  • 淋巴瘤亚型具有不同的VTE风险,且该效应独立于疾病负荷和全身治疗的使用。
  • Khorana风险评分在时间-事件分析中得到验证,并提出了更稳健的淋巴瘤特异性VTE风险评分。
  • 这些发现提示可通过基线参数识别VTE风险最高的淋巴瘤患者。

研究设计与样本

  • 回顾性分析,比较DLBCL与FL患者的VTE风险。
  • 790例患者于2002年至2014年诊断(DLBCL 542例,FL 248例),中位随访49个月。
  • 受试者被随机分配至训练集和验证集,以识别VTE危险因素并评估风险模型性能,包括Khorana评分。

主要发现

  • 共观察到106例VTE,DLBCL的5年累积发生率高于FL(16.3% vs 3.8%)。
  • 合并VTE患者5年总生存率为51.4%,无VTE患者为73.1%(P < .001)。
  • 训练队列中识别的基线VTE危险因素包括淋巴瘤亚型、既往VTE、ECOG体能状态≥2、白蛋白降低、钙升高、白细胞升高、绝对淋巴细胞计数或单核细胞计数升高以及巨块病变。
  • 在Khorana评分中加入新变量后,通过赤池信息准则和一致性指数衡量的性能得到改善。
  • 包含淋巴瘤亚型、白蛋白、白细胞计数和巨块病变的新风险模型在基于时间的ROC分析中得到验证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolic events (VTE) are a frequent complication of lymphoma. We conducted a retrospective analysis to compare VTE risk in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Subjects were randomly assigned to training and validation sets to identify risk factors of VTE and evaluate risk model performance, including the Khorana score. A group of 790 patients were diagnosed from 2002 to 2014 (DLBCL = 542, FL = 248). Median follow- up was 49 months. We observed 106 VTE, with higher incidence in DLBCL (5-year cumulative incidence = 16.3% vs 3.8% in FL patients). Five-year OS for patients with VTE was 51.4% vs 73.1% in patients without VTE (P < .001). Baseline VTE risk factors identified in the training cohort included lymphoma subtype, previous VTE, ECOG performance status ≥2, decreased albumin, increased calcium, elevated WBC, absolute lymphocyte count or monocyte count, and presence of bulky disease. Addition of new variables to the Khorana score improved its performance measured by Akaike information criterion and Concordance index. A new risk model including lymphoma subtype, albumin, WBC count, and bulky disease was validated in time-based ROC analyses. These findings were confirmed in the validation cohort. Lymphoma subtypes have different VTE risk. The effect of lymphoma subtype was independent from disease burden and the use of systemic therapy. The Khorana risk-score was validated in time to event analyses, and a more robust lymphoma-specific VTE risk score is proposed. These findings suggest lymphoma patients with highest VTE risk can be identified with baseline parameters.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dharmavaram G, Cao S, Sundaram S, et al. Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models. Am J Hematol. 2020. PMID: 32311162. doi:10.1002/ajh.25837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。